Krilogy Financial’s Acadia Pharmaceuticals ACAD Stock Holding History

Krilogy Financial’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-400	Closed	-$8K	–	142
2018 Q3	$8K	Buy	+400	New	+$6.29K	﹤0.01%	555
2018 Q2	–	Sell	-400	Closed	-$9K	–	151
2018 Q1	$9K	Hold	400	–	–	﹤0.01%	535
2017 Q4	$12K	Sell	400 -100	-20%	-$3.2K	﹤0.01%	499
2017 Q3	$19K	Sell	500 -100	-17%	-$3.25K	﹤0.01%	479
2017 Q2	$17K	Hold	600	–	–	﹤0.01%	455
2017 Q1	$17K	Hold	600	–	–	0.01%	439
2016 Q4	$17K	Hold	600	–	–	0.01%	439
2016 Q3	$19K	Hold	600	–	–	0.01%	445
2016 Q2	$19K	Buy	600 +100	+20%	+$3.35K	0.01%	448
2016 Q1	$14K	Hold	500	–	–	0.01%	429
2015 Q4	$18K	Buy	500 +100	+25%	+$3.52K	0.02%	211
2015 Q3	$13K	Buy	+400	New	+$16.6K	0.01%	355

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Krilogy Financial's ACAD Position: Q4 2018 in Review

Krilogy Financial sold out of Acadia Pharmaceuticals (ACAD) in Q4 2018, closing a stake of 400 shares — an estimated $8K sold.

Krilogy Financial first reported a position in ACAD in Q3 2015 and held it in 12 quarters. The position peaked at $19K in Q3 2017. 186 funds tracked by Wall St. Rank hold ACAD as of Q4 2018.

Krilogy Financial reported no remaining Acadia Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Krilogy Financial sold 400 Acadia Pharmaceuticals shares in Q4 2018, an estimated $8K.
Krilogy Financial first reported a position in Acadia Pharmaceuticals in Q3 2015 and held it in 12 quarters.
Krilogy Financial's Acadia Pharmaceuticals position peaked at $19K in Q3 2017.
186 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2018.

Based on Krilogy Financial's 13F filing for Q4 2018, filed 14 Feb 2019.